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Summary 
Aging is not only a major risk factor for impaired collateral growth under ischemia but 
also shortens the telomere length, which are regulated by telomerase. We examined the 
role of telomerase activity during impaired collateral growth during aging in ischemic 
skeletal muscle. Unilateral hindlimb ischemia was generated in old, young, and old mice 
chronically administered a telomerase activator. In old mice, blood flow recovery and 
development of capillary density in ischemic hindlimbs were reduced compared to those 
in young mice, and these changes were restored to equal levels by administration of TA-
65, a telomerase activator. During the early phase of ischemic muscle changes in old mice, 
expression of telomerase reverse transcriptase and telomerase activity were both low 
compared to those in young mice and old mice treated with TA-65. Levels of reactive 
oxygen species (ROS), DNA double-strand breaks, and expression of p53, p16, and 
Bax/Bcl-2 were all elevated in ischemic muscles of old mice compared to those in the 
muscles of young mice and old mice treated with TA-65 treatment; these factors were 
maintained at low levels equivalent to those seen in young mice during the experiment. 
Expression of HIF1-α/VEGF and PGC1α were decreased in old mice compared to those 
in young mice and old mice treated with TA-65. Collateral growth under ischemic 
conditions is impaired in aged animals due to low telomerase activity, increased ROS, 
resultant DNA damage, and expression of tumor suppressor and pro-apoptotic proteins. 
These data suggest that telomerase activation enhances collateral growth and rescues 
ischemic tissue in old individuals. 
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senescence is a major risk factor for cardiovascular disease including peripheral artery 
disease, and impaired angiogenesis occurs with aging. 1,2) A previous report demonstrated 
that recovery of blood flow after hindlimb ischemia is impaired in older mammals 
compared with young mammals.3) However, the mechanisms underlying this 
phenomenon remain unclear. 
Telomeres are chromatin structures composed of repetitive noncoding DNA sequences 
(TTAGGG in humans) at the ends of chromosomes that protect this region from 
degradation and recombination.4) Telomerase is a ribonucleoprotein composed of a 
catalytic subunit, telomerase reverse transcriptase (TERT) and a telomerase RNA 
template component (TERC) that prevents telomere shortening by adding telomeric DNA 
repeats to the ends of chromosomes.4) Telomere length is maintained by telomerase 
complex in normal stem cells; however, it gradually shortens with age in most somatic 
cells where telomerase is either absent or expressed at low levels. Telomere shortening 
can have a critical impact on stem cell proliferation, consequently inducing vascular cell 
senescence.5,6) On the other hand, apart from telomere elongation, accumulating evidence 
indicates that telomerase plays a role in telomere-independent mechanisms involved in 
vascular aging including in cellular proliferation, gene expression regulation and 
mitochondrial function.7,8) However, the role of telomerase during impaired collateral 
flow recovery in aging after hindlimb ischemia remains unclear. Therefore, we performed 
the present study to examine whether telomerase activation improves blood flow after 
acute hindlimb ischemia in aged mice.  
In this study, limb perfusion recovery in old mice treated with TA-65 was observed and 
compared to young, 8-week-old (8W) mice and old, 80-week-old (80W) mice. TA-65 is 
a single small organic molecule that is obtained from an extract of the roots of the plant 
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Astragalus membranaceus, which is commonly used in traditional Chinese medicine and 
has been identified as an effective telomerase activator.9-11) In previous study, it has been 
reported that TA-65 treatment of mice resulted in not only a significant 10-fold increase 
in TERT mRNA and protein level in a liver and other tissue but also increase in mRNA 
levels of Jun B and c-Myc, two transcription factors regulated by the Mitogen-activated 
protein kinase (MAPK) pathway, which is a known potential mediator of TA-65 action. 
Therefore, TA65 dependent-telomerase activation occurs through transcription factors 
regulated by the MAPK pathway, which may directly or indirectly regulate the mTERT 
promotor.8, 9 We demonstrate a pivotal role for telomerase activation in angiogenesis after 
acute hindlimb ischemia in old mice that occurs by suppressing age-related ROS and 
DNA damage and subsequently suppressing the expression of p53, p16, and apoptotic 
proteins.  
 
 
Methods 
Animals 
This study conformed to the Guide for the Care and Use of Laboratory Animals published 
by the U.S. National Institutes of Health (NIH Publication, 8th edition, 2011). Our 
research protocol was approved by the Fukushima Medical University Animal Research 
Committee [permit number 29074 (24 July 2017)], and all animal experiments were 
conducted in accordance with the guidelines of the Fukushima Medical University 
Animal Research Committee. All efforts were made to minimize animal suffering.  
Young and old wild-type C57BL/6 male mice [young: 8 weeks (W); body weight (B.W.), 
18.4±0.2 g; old: 80W; B.W., 29.3±0.5 g] were housed and bred in a room maintained at 
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22±3°C with a relative humidity of 50±10% and a 12-h light-dark cycle. Mice were given 
water ad libitum. 
 
Animal experiments 
Young mice were given saline, and old mice were administered either saline or the 
telomerase activator TA-65 (T.A. Sciences, Inc. NY, USA). 
In reference to doses used in past papers, TA-65 was dissolved in saline and administered 
at a dose of 25 mg/kg/day by oral gavage.9,12) Unilateral hindlimb ischemia was induced 
by the method described below at day 21 after saline or TA-65 administration. Saline and 
TA-65 administration were continued after hindlimb ischemia was induced, and mice 
were euthanized with isoflurane aspiration and a lethal dose of pentobarbital (60 mg/kg 
body weight i.p.) on postoperative day (POD) 3 or POD 21 followed by examinations 
described in context. We selected POD 3 and 21 based on the findings of our previous 
reports.13) 
 
Hindlimb ischemia 
The left femoral artery was exposed under tribromoethanol anesthesia (200 mg/kg/body 
weight, i.p.) and was ligated at two positions, just below the inguinal ligament and 
proximal to the saphenous-popliteal bifurcation using 6-0 sutures. Sham operations 
occurred without femoral artery ligation but with a skin incision made in the right 
hindlimb.  
 
Measurement of hindlimb perfusion 
Scanning laser Doppler perfusion imaging (Moor Instruments, Wilmington, DE, USA) 
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was used to measure hindlimb perfusion under 1.125% isoflurane/O2 anesthesia. The ratio 
of ischemic/nonischemic laser Doppler blood flow was measured before and on 
postoperative days 0, 1, 7, 14, and 21.  
 
Measurement of reactive oxygen species (ROS) 
An OxiSelectTM In Vitro ROS/RNS Assay Kit (Green Fluorescence) was used to measure 
levels of ROS according to the protocol provided by the manufacturer (Cell Biolabs, Inc. 
San Diego, CA, USA). Twenty milligrams of harvested soleus muscle tissues were cut to 
pieces 5 mm away from the Achilles tendon and homogenized in 1 ml of ice-cold PBS. 
Homogenized samples were centrifuged at 10,000 g for 5 min to remove insoluble 
particles. The supernatant of each sample was used. We added 50 μl of each sample in 
duplicate and hydrogen peroxide (H2O2) standards to a black 96-well plate with 50 μl of 
the provided catalyst solution and incubated the mixture for 5 min at room temperature 
to accelerate the oxidative reaction. Next, we added 100 μl of dichlorodihydrofluorescein 
(DCFH) solution included in the kit to each well, covered the plates to protect them from 
light and incubated the samples at room temperature for 30 min. Finally, fluorescence was 
read with a fluorescence plate reader (SpectraMaxⓇ i3, Molecular Devices) at 480 nm 
excitation/530 nm emission. A H2O2 standard curve was used to quantify total free radical 
content in skeletal muscle. 
 
Measurement of telomerase activity 
The telomerase repeated amplification protocol (TRAP) assay is a popular method to 
determine telomerase activity in mammalian cells and tissue samples.14) Telomerase 
activity was measured using the Telo TAGGG Telomerase PCR ELISAPLUS Assay Kit 
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(Cat. No. 12013789001, Roche Diagnostics GmbH, Mannheim, Germany), a photometric 
enzyme immunoassay for quantitative determination of telomerase activity that utilizes 
TRAP. Tissues extracts were prepared from frozen tissue pellets stored at -80°C by adding 
200 μl of lysis reagent according to the manufacturer’s instructions. The lysis mixture 
was homogenized and incubated on ice for 30 min. The lysate was then centrifuged at 
16,000 x g for 20 min at 4°C, and the supernatant was collected. We measured protein 
concentrations by standard methods and then performed the TRAP reaction as described 
below.  
First, negative controls for each sample were prepared by heating at 95°C for 10 min. 
Then, we prepared 30 μl of master mix (25 μl of reaction mixture, 5 μl of the provided 
internal standard) per sample. We constructed 50 μl reaction mixtures for each sample (30 
μl of master mix, X μl of sample per 10 μg of total protein and added nuclease free water 
for a total volume of 50 μl), negative controls (30 μl of master mix, X μl of heat-treated 
sample per 10 μg of total protein and added nuclease free water for a total volume of 50 
μl) and control templates (30 μl of master mix, with 1 μl of control template added to a 
separate tube, 1 μl of lysis reagent added to another tube and 19 μl of nuclease-free water 
added to each tube), all of which were added to a new 0.2-ml tube suitable for PCR. Then, 
microtubes were transferred to PCR thermal cycler (GeneAmpⓇ PCR system 9700, 
Applied Biosystems) for combined primer elongation/amplification reaction using the 
following protocol [1 cycle for 20 min at 25°C (primer elongation); 1 cycle for 5 min at 
94°C (telomerase inactivation); 30 cycles for 30 sec at 94°C, 30 sec at 50°C, 90 sec at 
72°C and 1 cycle for 10 min at 72°C (amplification, PCR)]. After 2.5 μl of amplification 
products were mixed with 10 μl of denaturation reagent, we added 100 μl of hybridization 
buffer according to the supplier’s instructions. Then, we transferred the 100-μl samples 
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to a precoated MP module included in the kit and incubated for 2 hours at room 
temperature with agitation at 300 rpm. Then, the MP modules were washed three times, 
and 100 μl of anti-DIG-HRP was added to each well and incubated for 30 min with 
agitation at 300 rpm. After washing the plates three times, 100 μl of prewarmed TMB 
substrate solution was added to the wells, and the wells were incubated at room 
temperature for 20 min with agitation for color development. Then, 100 μl of stop reagent 
was added to each well to stop color development. Finally, we measured sample 
absorbance at 450 nm using a microplate reader (with a reference wavelength of 
approximately 690 nm). 
Relative telomerase activity (RTA) was calculated using the following formula: 
 
(AS-AS0)/AS,IS 
RTA  =                            ×  100% 
(ATS8-ATS8,0)/ATS8,IS  
 
AS:    absorbance of the sample 
AS,0:       absorbance of heat- or RNase-treated samples 
AS,IS:   absorbance of the internal standard (IS) of the sample 
ATS8:      absorbance of the control template (TS8) 
ATS8,0:     absorbance of the lysis buffer 
ATS8,IS:     absorbance of the internal standard (IS) of the Control template (TS8) 
 
Western Blotting 
Harvested soleus muscles frozen at -80°C were pulverized in liquid nitrogen and 
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suspended in lysis buffer with a protease inhibitor. After determining protein 
concentrations using a standard protocol (Bradford protein assay, Bio-Rad), equal 
amounts of protein (20 μg/sample) were analyzed by 7.5%, 10% or 15% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels depending on the molecular 
weight of the targeted proteins. Gels were transferred onto nitrocellulose membranes that 
were blocked with tris-buffered saline Tween 20 (TBST) containing 5% bovine serum 
albumin (5% BSA) and immunoblotted using the following primary antibodies at 4°C 
with gentle agitation overnight: anti-p53 (PAb122) (Enzo Life Sciences, Inc., 
Farmingdale, NY, USA, 1:1000), anti-p21 (sc-6246) (Santa Cruz Biotechnology, Inc. 
1:1000), anti-p15/16 (sc-28260) (Santa Cruz Biotechnology, Inc. 1:1000), anti-histone 
H2A.X (phosphorS139) (ab81299) (Abcam plc, Cambridge, UK, 1:1000), anti-Bax 
(#2772) (Cell signaling Technology, Inc. 1:1000), anti-Bcl-2 (#2876) (Cell signaling 
Technology, Inc. 1:1000), anti-TERT (NB100-317) (Novus Biologicals, LLC., Littleton, 
CO, USA, 1:1000), anti-HIF-1α (#14179) (Cell signaling Technology, Inc. 1:1000), anti-
VEGF (sc-507) (Santa Cruz Biotechnology, Inc. 1:1000), anti-PGC1 alpha (ab54481) 
(Abcam plc, 1:1000) and anti-β-Actin (sc-47778) (Santa Cruz Biotechnology, Inc. 
1:10,000). Membranes were then washed in TBST and incubated with appropriate anti-
mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Santa Cruz 
Biotechnology, Inc. 1:10,000). Antibody -bound protein was visualized using enhanced 
chemiluminescence. Relative intensities of protein bands were quantified using NIH 
ImageJ, version 1.48 (Scion Image, NIH, Bethesda, MD, USA). Data were normalized to 
β-Actin and are expressed as fold change to the nonischemic skeletal muscle of young 
mice in the same period for each analysis. 
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Immunohistochemistry 
Capillary formation in ischemic soleus muscles was analyzed by immunostaining for 
CD31 and quantified as capillaries per muscle fiber. Immunohistochemistry was 
performed using paraffin-embedded tissue (IHC-P). 
First, we deparaffinized and rehydrated slides by immersion in the following solutions: 
xylene, four washes, 2 min each→100% ethanol, two washes, 2 min each→95% ethanol, 
2 min each→90% ethanol, 2 min each. Slides were washed with PBS three times for 5 
min each. For antigen retrieval, we brought slides to a boil in Histo VT One (10X, pH 7.0, 
Nacalaitesque, INC. Kyoto, JPN) buffer and maintained at subboiling temperature for 10 
min. We allowed slides to cool on the bench top for approximately 30 min. We incubated 
slides in 0.3% hydrogen peroxide in methanol for 20 min to quench endogenous 
peroxidase activity. We then washed the slides in PBS three times for 5 min each. We 
added primary antibody (rabbit anti-mouse CD31 antibody, Santa Cruz Biotechnology) 
diluted in 2% BSA-PBS and 0.05% sodium azide (1:50~1:100) and incubated them 
overnight at 4°C in a humidified chamber. Slides were washed with PBS three times for 
5 min each the following day. We then added secondary antibody (HRP-labeled Gout 
Anti-rabbit IgG, HistofineⓇ Simple StainTM Mouse MAX PO(R), Nichirei Biosciences, 
Tokyo, JPN) and incubated the slides at room temperature for 30 min. Slides were 
subsequently washed with PBS three times for 5 min each. 
3,3’-diaminobenzidine tetrahydrochloride (DAB; Wako Pure Chemicals Industries, Ltd. 
Tokyo, JPN) solution was prepared by mixing 100 ml of 0.05 M Tris buffer, 20 mg of 
DAB and 17 μl of 30% H2O2 (just before use). Slides were immersed in DAB solution for 
5 min to 10 min until chromogenic reaction turned the epitope sites brown. After washing 
slides with water, we stained the nuclei with hematoxylin and eosin (H.E.). 
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Slides were dehydrated by moving slides through the following solutions for 1 min per 
section: 70% ethanol → 95% ethanol → 100% ethanol, two washes → xylene, four 
washes. Finally, we added mounting media to the slides and topped them with coverslips. 
Capillary counts were performed under light microscopy (200x). The number of 
capillaries was measured in five randomly chosen fields from three different sections in 
each tissue block. 
 
Statistical Analysis 
All values are expressed as the means ± S.E.M. One-way repeated measures ANOVA with 
Tukey’s post hoc test used to compare hindlimb blood flow data. For all other data sets, 
one-way factorial ANOVA with Tukey’s post hoc test were performed to compare 
multiple groups. P<0.05 was considered to be statistically significant. All statistical 
analyses were performed using SPSS software (ver. 24.0, IBM, Armonk, NY, USA). 
 
Results 
Limb blood flow recovery  
Blood flow recovery was impaired in ischemic hindlimbs of old mice compared to those 
of young mice (Figure 1A and B). TA-65 treatment in old mice improved blood flow 
recovery. Histologically, TA-65 treatment also increased capillary density as measured by 
CD31 staining of muscle tissue in old mice, which reflected improved blood flow 
recovery (Figure 1C and D). These data support the notion that collateral flow recovery 
under ischemic conditions is impaired in aging and that telomerase activation by TA-65 
treatment could improve age-related impairment of angiogenesis. 
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Levels of ROS in skeletal muscle tissue 
Oxidative stress increasing with age, 15) and high levels of ROS are cytotoxic and impair 
angiogenesis.16) We previously reported that age-related increases in ROS levels after 
hindlimb ischemia impair limb blood flow recovery.17) We also demonstrated that 
mitochondrial ROS scavenging in old mice contributes to collateral flow recovery after 
hindlimb ischemia.13) Therefore, We initially measured levels of ROS in nonischemic and 
ischemic soleus muscles at POD 3. No difference was found among nonischemic animals 
(Figure 2A). Levels of ROS in ischemic limbs of old mice were elevated compared to 
those in nonischemic regions and were prominent compared to those in the limbs of young 
mice. Furthermore, ROS levels were attenuated by TA-65 treatment in old mice. These 
findings suggest that the levels of ROS increase in aging tissue under ischemia and are 
attenuated by TA-65 treatment. 
 
DNA damage in skeletal muscle tissue 
It has been reported that ROS, telomere dysfunction, UV exposure, etc., cause DNA 
damage responses (DDRs), in particular double-strand breaks (DSBs); DSBs are the most 
serious type of DNA damages and induce apoptosis and cellular senescence, resulting in 
vascular aging.18) DSBs trigger activation of many factors including phosphorylation of 
histone variant H2AX (γH2AX), which plays an important role in the DDR and is 
required for assembly of DNA repair proteins at sites containing damaged chromatin and 
for activation of checkpoint proteins that cause cell cycle arrest.19) Therefore, γH2AX is 
a useful tool for detecting DNA damage. To evaluate DNA damage in response to 
hindlimb ischemia, we measured γH2AX expression in soleus muscle by Western blotting. 
On POD 3 and POD 21, γH2AX expression increased in ischemic limbs compared to 
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nonischemic limbs (Figure 2B). In ischemic muscles, the expression levels of γH2AX 
were high in old mice compared to young mice and were attenuated in old mice treated 
with TA-65, resulting in levels equal to those in young animals. These results suggest that 
DNA damage in skeletal muscle induced by ischemia increases with aging and is 
suppressed by TA-65 treatment. 
 
TERT expression and telomerase activity 
The enzymatic activity of telomerase has been proposed to be primarily controlled by 
transcriptional regulation of TERT. TERT gene transfer into endothelial progenitor cells 
(EPCs) contributed to improvement in angiogenesis in a murine model of hindlimb 
ischemia.20) Thus, impaired TERT expression and telomerase activity may contribute to 
impaired angiogenesis in the elderly. We measured TERT expression and telomerase 
activity to investigate the effects on aging in response to ischemia and to confirm 
telomerase activation by TA-65. On POD 3, TERT expression and telomerase activity 
were significantly elevated in ischemic limbs compared to nonischemic limbs (Figure 3A 
and B). In ischemic muscles, TERT expression and telomerase activity in old mice were 
reduced compared to those in young mice and were upregulated in old mice by TA-65 
treatment. In contrast, on POD 21, TERT expression was higher in old mice than in young 
mice, and the same tendency was found in TERT levels between young mice and old mice 
treated with TA-65. TA-65 treatment regulated TERT levels at POD 21 and POD 3. In 
contrast, the effect of TA-65 on telomerase activity at POD 21 in ischemic limbs in old 
mice was negligible. 
It has been reported that TERT expression is upregulated in response to cellular stress, 
such as that caused by ischemia.21) On POD 21, blood flow recovery in ischemic 
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hindlimbs of young and TA-65-treated old mice were improved to nearly the same level 
as in nonischemic mice, as described above. Therefore, we proposed that there was a 
reduced influence of hypoxia and ischemia in young mice and in old mice treated with 
TA-65 during the late phase of ischemia. These data suggest that TERT expression and 
telomerase activity that were upregulated in response to ischemia were attenuated in the 
elderly, especially during the early phase of hindlimb ischemia, and were recovered after 
TA-65 treatment.  
 
Expression of p53/p21, p15/16 and apoptotic factors 
Telomere shortening or DNA damage induces DDR. When damage becomes irreversible, 
the DDR pathway induces cellular senescence, cell-cycle arrest and apoptosis. The 
transcription factor p53, also known as a tumor suppressor gene, is widely recognized as 
one of the downstream effectors in the DDR pathway that plays an important role through 
activating pathways via posttranslational modifications, such as acetylation or 
phosphorylation. Considering our findings that TA-65 decreased ROS levels and DNA 
damage, we assumed that TA-65 treatment would attenuate p53 expression. Thus, we 
examined whether TA-65 treatment downregulated p53 or p21 expression in ischemic 
aged skeletal muscles. In nonischemic groups, p53 expression on POD 3 and POD 21 in 
old mice tended to be high compared to that in young mice and TA-65 treated mice 
(Figure 4A). p53 expression was higher in ischemic old mice than in nonischemic mice 
and was attenuated by treatment with TA-65 (Figure 4B). Expression of p21 showed the 
same tendency, and a similar trend was recognized in p53/p21 expression on POD 3 and 
POD 21 (Figure 4C). The p16/RB (retinoblastoma protein) pathway is also another major 
pathway of senescence. Aging and many inducers of cellular senescence, such as ROS, 
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increase p16 activity.22) We measured p16 expression at POD 3 and POD 21, and found 
that expression was higher in ischemic old mice than in nonischemic limbs and was 
decreased in TA-65-treated old mice (Figure 4D). These findings suggest that a decline 
in ROS and subsequent DNA damage with TA-65 treatment in aged skeletal muscle 
attenuate p53/p21 and p16 expression in response to ischemia. Apoptosis, a programmed 
form of cell death, is considered an anti-angiogenetic mechanism.23) Several studies have 
reported that telomerase activity is essential for endothelial cell differentiation and 
protection from apoptosis.24) The B-cell leukemia/lymphoma-2 (Bcl-2) family of proteins 
are the best-characterized protein family involved in regulation of apoptotic cell death 
and includes anti-apoptotic and pro-apoptotic members. Activated p53 in response to 
DNA damage mediates mitochondrial control of apoptosis by promoting pro-apoptotic 
members (Bax) and suppressing anti-apoptotic Bcl-2.25) Therefore, we examined whether 
telomerase activation prevents apoptosis under conditions of ischemia. The Bax/Bcl-2 
ratio was higher in ischemic old mice than in young mice, and TA-65 treatment of old 
mice decreased the Bax/Bcl-2 ratio to that of young mice at both POD 3 and POD 21 
(Figure 4E). These data suggest that telomerase activation by TA-65 is protective against 
ischemia-induced apoptosis in aged skeletal muscle and contributes to angiogenesis. 
 
HIF-1α-VEGF signaling pathways 
Ischemia-induced angiogenesis is impaired in aging and is mediated by hypoxia inducible 
factor-1 (HIF-1α).26) HIF-1α is a transcription factor that mediates adaptive responses to 
hypoxia and ischemia. HIF-1α regulates expression of angiogenetic factors, such as 
vascular endothelial growth factor (VEGF), via the HIF-1α-VEGF signaling pathways.27) 
p53 is known as a potent negative regulator of HIF-1α and VEGF during hypoxia.28) To 
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examine the angiogenetic effects of TA-65 treatment, we measured expression of HIF-1α 
and VEGF by Western blot analysis (Figure 5A). At POD 3, expression of HIF-1α and 
VEGF were significantly increased in young mice compared to nonischemic mice (Figure 
5B and C). This elevation was suppressed in old mice and recovered with TA-65 treatment. 
However, on POD 21, expression of HIF-1α was not different among the three groups. 
Expression of VEGF in young mice was higher than that in old mice, and there was a 
tendency for increased expression of VEGF in old mice treated with TA-65 compared to 
those that were not treated, though this change did not reach statistical significance. These 
data suggest that telomerase activation by TA-65 is associated with elevated HIF-1α and 
VEGF expression in aged skeletal muscle at comparatively early phases of ischemia. On 
POD 21, blood flow recovery in ischemic hindlimbs of young mice and TA-65-treated 
old mice improved to nearly the same level as in nonischemic mice described above. 
Therefore, we propose that hypoxia and ischemia exert less of an influence in young mice 
and in old mice treated with TA-65 than in untreated old mice during the late phase of 
ischemia. 
 
Expression of peroxisome proliferator activated receptor γ coactivator 1α (PGC-1α) 
Recent studies have reported that telomere dysfunction and associated DNA damage 
responses promote mitochondrial dysfunction.29) p53 induced by telomere dysfunction 
binds to the PGC-1α promoter and suppresses expression of PGC-1α. Repression of PGC-
1α impairs mitochondrial biogenesis and function, resulting in reduced ATP generation 
and increased levels of ROS.30) In light of our previous experiments illustrating that 
telomerase activation by TA-65 attenuates ROS and DNA damage along with decreasing 
p53 levels in aged ischemic skeletal muscle, we assumed that TA-65 treatment would 
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preserve PGC1α expression under conditions of ischemia. Expression of PGC-1α did not 
differ in the nonischemic skeletal muscles at POD 3 or POD 21. In ischemic skeletal 
muscles at POD 3, expression of PGC-1α was significantly lower in old mice than in 
young mice, and TA-65 treatment of old mice maintained PGC-1α levels at similar levels 
as those in young mice (Figure 5D). However, there were no differences in PGC-1α 
expression in ischemic skeletal muscle at POD 21. Considering the reduction in ROS, 
protection from apoptosis, and preservation of PGC-1α expression by TA-65 treatment in 
ischemic aged mice, these data suggest that telomerase activation improves mitochondrial 
dysfunction in aged mice after hindlimb ischemia, especially during early phases of 
ischemia. 
 
Discussion 
Senescence is a dominant risk factor for most forms of cardiovascular disease.31) 
Telomerase is closely related with cellular senescence and is suspected to be a potential 
anti-aging therapy.32) Our present study demonstrates the crucial role of telomerase 
activity for improving blood flow after acute hindlimb ischemia in old mice. Telomerase 
activation therapy in aged skeletal muscle suppresses age-related ROS and DNA damage 
in response to ischemia, contributing to angiogenesis through the tumor suppressors p53 
and p16 and pro-apoptotic proteins.  
The tumor suppressors p53 and p16 are upregulated in response to various cellular 
stresses, including DNA damage, oxidative stress and hypoxia.19,33-35) Upregulation of 
p53 induces dramatic and multiple cellular responses including apoptosis and anti-
angiogenesis via the HIF-1α/VEGF pathway.36,37) In the present study, as in our previous 
study13), p53 was upregulated by aging and in response to ischemic DNA damage, which 
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seemed to promote apoptotic processes and inhibit angiogenetic processes. Telomerase 
activation markedly downregulated p53 expression in response to ischemia. Considering 
that DDR following DNA damage is the most important pathway for p53 upregulation, 
reduction of ROS and DNA damage by telomerase activation are the most likely reasons 
for downregulation of p53. On the other hand, it has been reported that p16 also modulates 
VEGF expression through HIF-1α.38) Thus, telomerase activation under conditions of 
ischemia may contribute to angiogenesis not only through p53 downregulation but also 
through p16 reduction, resulting in collateral flow recovery. 
Furthermore, apoptosis is considered an anti-angiogenetic mechanism, and p53 
activated due to cellular stress mediates mitochondrial control of apoptosis.23,25) 
Considering the observed downregulation of p53 and the Bax/Bcl-2 ratio in ischemic 
muscle, telomerase activation might contribute to inhibiting apoptosis, resulting in 
angiogenesis and collateral flow recovery. In this study, we examined apoptosis in 
isolated muscle including vessel, because it is difficult to isolate capillary. Therefore 
further study is needed like an in vitro study to clarify the pure contribution of TA-65 to 
angiogenesis and apoptosis. 
It has been proposed that the enzymatic activity of telomerase is primarily controlled 
by transcriptional regulation of TERT, as shown in our results at POD 3. In contrast, there 
are many reports that telomerase activity is regulated by several factors, such as ROS, 
exercise capacity and cellular stress related to the magnitude of ischemia,32,39,40) which 
may affect TERT expression and telomerase activity in chronic ischemic conditions, as 
we did not observe a positive correlation between telomerase activity and TERT 
expression in ischemic old mice at POD 21. Therefore, further study is needed to 
investigate the effect of telomerase on various conditions, including acute and chronic 
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ischemic states. TERT has also been proposed to play a role in regulating oxidative 
damage-induced apoptosis. Oxidative stress triggers nuclear export of TERT to the 
mitochondria.41) TERT has been shown to localize to mitochondria and contributes 
different mitochondrial functions (such as modulating mtDNA integrity, improving 
respiratory chain function and affecting ROS production).30) Therefore, we believe that 
the main source of ROS is mitochondria. As previously presented, the chronic scavenging 
of superoxide that is dropped from mitochondria ETc-complex in aged skeletal muscle 
like a condition with attenuated telomerase activity, improved collateral growth induced 
by ischemia through regulation of p53 as a mimicking effect of TA-65 treatment.13) 
Therefore, mitochondria ETc-complex activity or drop of superoxide from ETc-complex 
pathway might be modified by telomerase activity and TA-65 decrease generation of 
superoxide in ETc-complex in mitochondria, though further study is needed to clarify the 
telomerase effect to mitochondria. Thus, antioxidant effect of telomerase or TA-65 is to 
reduce the generation of superoxide from ETc-complex in mitochondria. PGC-1α is a 
master regulator of mitochondrial physiology and metabolism. Furthermore, PGC-1α 
induces VEGF and contributes to angiogenesis.42) Telomere dysfunction activates p53, 
which in turn binds and represses PGC-1α promotors, inducing mitochondrial 
dysfunction that promotes ATP synthesis and increased ROS.29) Considering the observed 
reduction in ROS, protection from apoptosis, and preservation of PGC-1α expression by 
telomerase activation during the early phase of ischemia in old mice, increased telomerase 
activity could improve mitochondrial dysfunction and contribute to angiogenesis through 
preservation of PGC-1α in aged skeletal muscle after hindlimb ischemia. 
There are a few limitations to this study. First, we did not measure telomere length in 
this study. In recent years, evidence of the additional functions of telomerase other than 
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telomere maintenance have been accumulating.7,8) Human adult somatic cells do not 
express telomerase activity, whereas most adult mouse somatic cells including skeletal 
muscle express detectable amounts of telomerase.43) In fact, it has been reported that there 
is no significant difference in telomere length between young and aged muscle stem cells, 
known as satellite cells, from uninjured wild-type mice.44) Considering the lack of 
differences in telomere length in response to aging in the skeletal muscles of mice, the 
rapid onset of the anti-apoptotic process and angiogenetic differences in old mice treated 
with TA-65 detectable at day three in vitro seems to depend on telomerase rather than on 
telomere length. Second, we evaluated only two time points, POD 3 and POD 21 
(reference our previous study).13) It is presumed that signal transduction including TERT 
may dramatically change, especially during the early phase of ischemia, but we did not 
demonstrate sequential changes. Third, we did not perform measurements in muscles 
composed of fast-twitch muscle fibers, such as the gastrocnemius. It has been reported 
that age-related mitochondrial function, one of the important targets of telomerase, varies 
in different muscle types,45,46)  thus the further study is needed to investigate the 
telomerase performance in other muscle types. Finally, cycloastragenol (CAG), the main 
component of TA-65, is a molecule isolated from Astragalus. There is a few report that 
CAG enhanced antioxidant capacity in itself in a D-galactose-induced senescence mouse 
model and its antioxidant effects may be related to the hydroxyl found in the chemical 
structure of CAG.47)  Since oxidative stress is a main reason for telomere dysfunction 
and anti-angiogenesis, we could not completely exclude the possibility that the telomere 
protective and angiogenetic effects of TA-65 may be related to not only telomerase 
activation but also its direct antioxidative effects. 
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Conclusion 
We showed a possible role for telomerase in regulating cellular processes during 
senescence other than telomere elongation, such as differentiation and angiogenesis, 
through the tumor suppressors p53 and p16. Our data suggest that telomerase plays a 
pivotal role in collateral development, and its pharmaceutical activation may be a novel 
therapeutic option to enhance collateral flow recovery to rescue ischemic tissue in elderly 
individuals.  
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Figure 1. Changes in ischemic limb blood flow and capillary density.  
Recovery of ischemic limb blood flow measured by Doppler flow imaging was impaired 
in old mice compared to young mice. TA-65 treatment in old mice improved blood flow 
recovery. (A) Representative data. (B) Changes in blood flow. Histologically, TA-65 
treatment increased capillary density measured by CD31 staining of the muscle with old 
mice. (C) Representative data. The arrow shows a capillary. (D) Summarized data. POD: 
postoperative day. Data are expressed as the means ± S. E. M. n=18, each, *P<0.05 vs. 
young mice. $ P<0.05 vs. old mice. 
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Figure 2. ROS generation and DNA damage in ischemic muscle. 
Levels of ROS (A) and γH2AX (B) in ischemic limbs in old mice were elevated compared 
to nonischemic regions and ischemic muscles of young mice; these changes were 
attenuated in old mice by TA-65 treatment. POD: postoperative day. Data are expressed 
as the means ± S. E. M. n=18, each, *P<0.05 vs. young mice. $ P<0.05 vs. old mice. # 
P<0.05 vs. nonischemic muscle. 
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Figure 3. TERT expression and telomerase activity. 
On postoperative day (POD) 3, TERT expression (A) and telomerase activity (B) were 
elevated under conditions of ischemia compared to nonischemic conditions. In ischemic 
groups on POD 3, TERT expression levels and telomerase activity in old mice were lower 
than those in young mice and were upregulated in old mice with TA-65 treatment. Data 
are expressed as the means ± S. E. M. n=18, each, *P<0.05 vs. young mice. $ P<0.05 vs. 
old mice. # P<0.05 vs. nonischemic muscle. 
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Figure 4. Expression of p53, p21, p16 and apoptotic factors. 
Representative Western blots shown in (A). Expression levels of each protein were 
normalized by -actin. p53 (B) and p21 (C) expression levels were higher in ischemic old 
mice than in nonischemic groups and were attenuated in old mice by administration of 
TA-65. On postoperative day (POD) 3 and 21, p16 (D) expression levels and the Bax/Bcl-
2 ratio (E) were higher in ischemic old mice than in nonischemic mice. In ischemic groups, 
p16 expression levels and the Bax/Bcl-2 ratio in old mice were higher than those in young 
mice and were attenuated in old mice by administration of TA-65. Data are expressed as 
the means ± S. E. M. n=18, each, *P<0.05 vs. young mice. $ P<0.05 vs. old mice. # P<0.05 
vs. nonischemic muscle. 
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Figure 5. Expression of HIF-1α, VEGF, and PGC-1α. 
On postoperative day (POD) 3 after induction of ischemia, expression of HIF-1α and 
VEGF were increased in young mice compared to nonischemic mice (A, B, C). These 
elevations were suppressed in old mice and upregulated by TA-65 treatment. However, 
on POD 21 after induction of ischemia, expression of these factors were not different 
among the three groups. Furthermore, in ischemic skeletal muscles on POD 3, expression 
of PGC-1α was reduced in old mice compared to young mice, and TA-65 treatment 
preserved PGC-1α to a similar level as in young mice (D). However, there were no 
differences in PGC-1α expression in ischemic skeletal muscle on POD 21. (A) 
Representative Western blots. (B, C, D) Summarized data. Data are expressed as the 
means ± S. E. M. n=18, each, *P<0.05 vs. young mice. $ P<0.05 vs. old mice. # P<0.05 
vs. nonischemic muscle. 
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Figure 6. Working hypothesis. 
Telomerase is activated by ischemia; however, senescence increases reactive oxygen 
species (ROS) and attenuates telomerase activity and inhibits collateral growth by 
increased p53 and p16 activity under conditions of ischemia. Therefore, telomerase 
activation may be a novel therapeutic option for enhancing collateral flow recovery and 
rescuing ischemic tissue in elderly individuals. 
 
 
34 
 
Abbreviations:   
TERT telomerase reverse transcriptase 
TERC telomerase RNA template component 
ROS reactive oxygen species 
POD post-operative days 
CVD cardiovascular disease 
PAD peripheral artery disease  
H2O2 hydrogen peroxide 
DCFH dichlorodihydrofluorescin  
TRAP Telomerase Repeated Amplification Protocol  
RTA The relative telomerase activity  
DDR DNA damage response  
DSBs double strand break  
γH2AX histone variant H2AX  
RB retinoblastoma protein 
HIF-1α Hypoxia inducible factor-1α  
VEGF vascular endothelial growth factor 
PGC1α proliferator activated receptor γ co-activator 1α  
Bcl2 B-cell leukemia/lymphoma 2 
Bax Bcl2-associated X 
 
 
